PMCC Staff Publications

pmcc logo sml

 

 Here are the staff publications for March 2022.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 11th April 2022.

 

1. Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol 2022;18:1185-98.

2. Albarakati H, Jackson P, Gulal O, Ramachandran P, Osbourne G, Liu M, Kron T, Geso M. Dose assessment for daily cone-beam CT in lung radiotherapy patients and its combination with treatment planning. Phys Eng Sci Med 2022;45:231-7.

3. Antill Y, Buchanan DD, Scott CL. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. Cancer 2022;128:1157-61.

4. Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, Roug AS, Cazzola M, Döhner H, Tefferi A. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. Am J Hematol 2022;97:514-8.

5. Asfia A, Deepak B, Novak JI, Rolfe B, Kron T. Multi-jet fusion for additive manufacturing of radiotherapy immobilization devices: Effects of color, thickness, and orientation on surface dose and tensile strength. J Appl Clin Med Phys 2022;23:e13548.

6. Aung E, Pasanen L, LeGautier R, McLachlan SA, Collins A, Philip J. The role of telehealth in oncology care: A qualitative exploration of patient and clinician perspectives. Eur J Cancer Care (Engl) 2022;31:e13563.

7. Bandala-Sanchez E, Roth-Schulze AJ, Oakey H, Penno MAS, Bediaga NG, Naselli G, Ngui KM, Smith AD, Huang D, Zozaya-Valdes E, Thomson RL, Brown JD, Vuillermin PJ, Barry SC, Craig ME, Rawlinson WD, Davis EA, Harris M, Soldatos G, Colman PG, Wentworth JM, Haynes A, Morahan G, Sinnott RO, Papenfuss AT, Couper JJ, Harrison LC, Group ES. Women with type 1 diabetes exhibit a progressive increase in gut Saccharomyces cerevisiae in pregnancy associated with evidence of gut inflammation. Diabetes Res Clin Pract 2022;184:109189.

8. Bean HR, Diggens J, Ftanou M, Alexander M, Stafford L, Bei B, Francis PA, Wiley JF. Light enhanced cognitive behavioral therapy for insomnia and fatigue during chemotherapy for breast cancer: a randomized controlled trial. Sleep 2022;45.

9. Bishop E, Miller C, Miller S, McKellar C. How staying in a single room affects the experiences of haematology inpatients in an Australian cancer hospital. Br J Nurs 2022;31:S22-s9.

10. Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, Wei AH, Hayslip J, Miles D, Mensing S, Gopalakrishnan S, Zha J. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 2022;40:269-79.

11. Breast Cancer Association C, Mavaddat N, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R, Bolla MK, Dennis J, Wang Q, Ahearn TU, Andrulis IL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Briceno I, Bruning T, Camp NJ, Campbell A, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Christiansen H, Czene K, Dork T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Geisler J, Giles GG, Guenel P, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Hartikainen JM, Hartman M, Hoppe R, Howell A, Jakubowska A, Jung A, Khusnutdinova EK, Kristensen VN, Li J, Lim SH, Lindblom A, Loizidou MA, Lophatananon A, Lubinski J, Madsen MJ, Mannermaa A, Manoochehri M, Margolin S, Mavroudis D, Milne RL, Mohd Taib NA, Morra A, Muir K, Obi N, Osorio A, Park-Simon TW, Peterlongo P, Radice P, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sim X, Southey MC, Thorne H, Tomlinson I, Torres D, Truong T, Yip CH, Spurdle AB, Vreeswijk MPG, Dunning AM, Garcia-Closas M, Pharoah PDP, Kvist A, Muranen TA, Nevanlinna H, Teo SH, Devilee P, Schmidt MK, Easton DF. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol 2022;8:e216744.

12. Busch K, Davidson A, Di Ieva A, Assaad N, Butlin M, Avolio A, Kiat H. Significant venous flow alterations following brain arteriovenous malformation Surgery: Assessment by transcranial colour duplex. J Clin Neurosci 2022;99:268-74.

13. Castiblanco D, Rudd-Schmidt JA, Noori T, Sutton VR, Hung YH, Flinsenberg T, Hodel AW, Young ND, Smith N, Bratkovic D, Peters H, Walterfang M, Trapani JA, Brennan A, Voskoboinik I. Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick Syndrome type C1. Blood 2022;139:1833-49.

14. Castiblanco D, Rudd-Schmidt JA, Noori T, Sutton VR, Hung YH, Flinsenberg TWH, Hodel AW, Young ND, Smith N, Bratkovic D, Peters H, Walterfang M, Trapani JA, Brennan AJ, Voskoboinik I. Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1. Blood 2022;139:1833-49.

15. Chan RJ, Agbejule OA, Yates PM, Emery J, Jefford M, Koczwara B, Hart NH, Crichton M, Nekhlyudov L. Outcomes of cancer survivorship education and training for primary care providers: a systematic review. J Cancer Surviv 2022;16:279-302.

16. Chee L, Ritchie D, Ludford-Menting M, Ripley J, Chung J, Park D, Norton S, Kenealy M, Koldej R. Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). Eur J Haematol 2021;108:342-53.

17. Chee L, Ritchie D, Ludford-Menting M, Ripley J, Chung J, Park D, Norton S, Kenealy M, Koldej R. Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). Eur J Haematol 2022;108:342-53.

18. Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Láng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S. Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst 2022;114:467-70.

19. Cohen PA, Webb PM, King M, Obermair A, Gebski V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileshkin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. Int J Gynecol Cancer 2022;32:560-5.

20. Comberlato A, Koga MM, Nüssing S, Parish IA, Bastings MMC. Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials. Nano Lett 2022;22:2506-13.

21. Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O'Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. Int J Cancer 2022;150:993-1006.

22. Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Morris J, Iddawela M, Mackay G, Jefford M. Defining research and infrastructure priorities for cancer survivorship in Australia: a modified Delphi study. Support Care Cancer 2022;30:3805-15.

23. Dall GV, Hamilton A, Ratnayake G, Scott C, Barker H. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit. Cancers (Basel) 2022;14.

24. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmana J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, Collaborators GS, Collaborators G-HS, Collaborators E, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dork T, du Bois A, Durst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, Group OS, Group A, Hahnen E, Haiman CA, Hakansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Hogdall E, Hogdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Investigators KC, Investigators H, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubinski J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamarina M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB, Consortium O, Consortium C, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet 2022;30:349-62.

25. Dark C, Cheung S, Cheng LY. Analyzing cachectic phenotypes in the muscle and fat body of Drosophila larvae. STAR Protoc 2022;3:101230.

26. Davies A, Mathur N, Lau T, Crossett M, Lau KK. Venous air embolism in CT coronary angiography. J Med Imaging Radiat Oncol 2022;66:351-6.

27. Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res 2022;28:1302-12.

28. Doig KD, Fellowes A, Scott P, Fox SB. Tumour mutational burden: an overview for pathologists. Pathology 2022;54:249-53.

29. Doig KD, Love CG, Conway T, Seleznev A, Ma D, Fellowes A, Blombery P, Fox SB. Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. BMC Med Genomics 2022;15:70.

30. Du X, Darcy PK, Wiede F, Tiganis T. Targeting PTPN22 does not enhance the efficacy of CAR T cells in solid tumours. Mol Cell Biol 2022;42:MCB0044921.

31. Du X, Darcy PK, Wiede F, Tiganis T. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. Mol Cell Biol 2022;42:e0044921.

32. Dunn J, McCuaig RD, Tan AHY, Tu WJ, Wu F, Wagstaff KM, Zafar A, Ali S, Diwakar H, Dahlstrom JE, Bean EG, Forwood JK, Tsimbalyuk S, Cross EM, Hardy K, Bain AL, Ahern E, Dolcetti R, Mazzieri R, Yip D, Eastgate M, Malik L, Milburn P, Jans DA, Rao S. Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8(+) T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers (Basel) 2022;14.

33. Finnegan RN, Reynolds HM, Ebert MA, Sun Y, Holloway L, Sykes JR, Dowling J, Mitchell C, Williams SG, Murphy DG, Haworth A. A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy. Phys Imaging Radiat Oncol 2022;21:136-45.

34. Freifeld Y, Pedrosa I, McLaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG, Porta C, Bucknell NW, Siva S, Brugarolas J, Margulis V, Timmerman R, Hannan R. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. Urol Oncol 2022;40:166.e9-.e13.

35. Gambell P, Rowley G, Pham TAT, Dang TL, Mulumba H, Smith L, Lakos G. Accurate white blood cell differential by Alinity hq: A comparison with flow cytometry and manual differential. Int J Lab Hematol 2022;44:288-95.

36. Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. Eur J Cancer 2022;166:219-28.

37. Gill JG, Leef SN, Ramesh V, Martin-Sandoval MS, Rao AD, West L, Muh S, Gu W, Zhao Z, Hosler GA, Vandergriff TW, Durham AB, Mathews TP, Aurora AB. A Short Isoform of Spermatogenic Enzyme GAPDHS Functions as a Metabolic Switch and Limits Metastasis in Melanoma. Cancer Res 2022;82:1251-66.

38. Goh Y, Kim D, Kim JY, Kim HS, Jeong JH, Lee SU, Youn SH, Oh ES, Ha BR, Yeo AU, Kim M, Shin D, Lee SB, Kim YJ, Kim TH, Lim YK. Active small bowel sparing in intracavitary brachytherapy for cervical cancer. Jpn J Clin Oncol 2021;52:266-73.

39. Goh Y, Kim D, Kim JY, Kim HS, Jeong JH, Lee SU, Youn SH, Oh ES, Ha BR, Yeo AU, Kim M, Shin D, Lee SB, Kim YJ, Kim TH, Lim YK. Active small bowel sparing in intracavitary brachytherapy for cervical cancer. Jpn J Clin Oncol 2022;52:266-73.

40. Gondoputro W, Thompson J, Evans M, Bolton D, Frydenberg M, Murphy DG, Haynes AM, Agrawal S, Stricker P, Papa N. How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. J Urol 2022;207:1048-56.

41. Grobler AC, Lee KJ, Wong A, Currow DC, Braat S. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework. J Pain Symptom Manage 2021;63:e431-e9.

42. Grobler AC, Lee KJ, Wong A, Currow DC, Braat S. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework. J Pain Symptom Manage 2022;63:e431-e9.

43. Heazlewood SY, Ahmad T, Mohenska M, Guo BB, Gangatirkar P, Josefsson EC, Ellis SL, Ratnadiwakara M, Cao H, Cao B, Heazlewood CK, Williams B, Fulton M, White JF, Ramialison M, Nilsson SK, Änkö ML. The RNA-binding protein SRSF3 has an essential role in megakaryocyte maturation and platelet production. Blood 2022;139:1359-73.

44. Hegarty S, Hardcastle N, Korte J, Kron T, Everitt S, Rahim S, Hegi-Johnson F, Franich R. Please Place Your Seat in the Full Upright Position: A Technical Framework for Landing Upright Radiation Therapy in the 21(st) Century. Front Oncol 2022;12:821887.

45. Hegi-Johnson F, Rudd S, Hicks RJ, De Ruysscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, MacManus MP. Imaging immunity in patients with cancer using positron emission tomography. NPJ Precis Oncol 2022;6:24.

46. Heinze K, Nazeran TM, Lee S, Kramer P, Cairns ES, Chiu DS, Leung SC, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitz F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FK, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Toloczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PD, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Kobel M, Anglesio MS. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol 2021;256:388-401.

47. Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SC, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommoss F, Vollert HW, Heitz F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommoss FK, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringe KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PD, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommoss S, Talhouk A, Köbel M, Anglesio MS. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. J Pathol 2022;256:388-401.

48. Heitink L, Whittle JR, Vaillant F, Capaldo BD, Dekkers JF, Dawson CA, Milevskiy MJG, Surgenor E, Tsai M, Chen HR, Christie M, Chen Y, Smyth GK, Herold MJ, Strasser A, Lindeman GJ, Visvader JE. In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis. Mol Oncol 2022;16:1119-31.

49. Holliday H, Yang J, Dodson E, Nikolic I, Kamili A, Wheatley M, Deng N, Alexandrou S, Davis TP, Kavallaris M, Caldon CE, McCarroll J, De Preter K, Mestdagh P, Marshall GM, Simpson KJ, Fletcher J, Swarbrick A. miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. Mol Ther 2022;30:1119-34.

50. Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, Léon-Castillo A, Krog RT, de Boer SM, Nout RA, Powell ME, Mileshkin LR, MacKay H, Leary A, Singh N, Jürgenliemk-Schulz IM, Smit V, Creutzberg CL, Koelzer VH, Nijman HW, Bosse T, de Bruyn M. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun 2022;13:1373.

51. Hübner M, Alyami M, Villeneuve L, Cortés-Guiral D, Nowacki M, So J, Sgarbura O. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. Eur J Surg Oncol 2022;48:789-94.

52. Ierano C, Rajkhowa A, Gotterson F, Marshall C, Peel T, Ayton D, Thursky K. Opportunities for nurse involvement in surgical antimicrobial stewardship strategies: A qualitative study. Int J Nurs Stud 2022;128:104186.

53. Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation Dosimetry in (177)Lu-PSMA-617 Therapy. Semin Nucl Med 2021;52:243-54.

54. Jackson TD, Crameri JJ, Muellner-Wong L, Frazier AE, Palmer CS, Formosa LE, Hock DH, Fujihara KM, Stait T, Sharpe AJ, Thorburn DR, Ryan MT, Stroud DA, Stojanovski D. Sideroflexin 4 is a complex I assembly factor that interacts with the MCIA complex and is required for the assembly of the ND2 module. Proc Natl Acad Sci U S A 2022;119:e2115566119.

55. Jalali A, Gard G, Banks S, Dunn C, Wong HL, Wong R, Lee M, Gately L, Loft M, Shapiro JD, Kosmider S, Tie J, Ananda S, Yeung JM, Jennens R, Lee B, McKendrick J, Lim L, Khattak A, Gibbs P. Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. Curr Probl Cancer 2022;46:100793.

56. Jiang W, Lokuhetty N, Mohan HM, Larach JT, Waters P, Heriot AG, Warrier SK. How to do a robotic lateral pelvic side wall dissection for rectal cancer. ANZ J Surg 2022;92:540-2.

57. Johnson DN, Ruan Z, Petley EV, Devi S, Holz LE, Uldrich AP, Mak JYW, Hor JL, Mueller SN, McCluskey J, Fairlie DP, Darcy PK, Beavis PA, Heath WR, Godfrey DI. Differential location of NKT and MAIT cells within lymphoid tissue. Sci Rep 2022;12:4034.

58. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer 2022;165:97-112.

59. Kim S, Pitson G, Koh TL, Chao M, Byrne K, Hornby C, Foroudi F, Millar J, Ong WL. Increasing use of post-mastectomy hypofractionated radiation therapy for breast cancer in Victoria. J Med Imaging Radiat Oncol 2022;66:428-35.

60. Koo K, Papa N, Evans M, Jefford M, M IJ, White V, Evans SM, Ristevski E, Emery J, Millar J. Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. BMC Cancer 2022;22:283.

61. Kron T. Cui Bono, Proton Radiotherapy? Clin Oncol (R Coll Radiol) 2022;34:258-60.

62. Lasocki A, Seymour JF. Central nervous system manifestations of systemic haematological malignancies and key differentials. Clin Radiol 2022;77:328-36.

63. Lau LMS, Mayoh C, Xie J, Barahona P, MacKenzie KL, Wong M, Kamili A, Tsoli M, Failes TW, Kumar A, Mould EVA, Gifford A, Chow SO, Pinese M, Fletcher JI, Arndt GM, Khuong-Quang DA, Wadham C, Batey D, Eden G, Trebilcock P, Joshi S, Alfred S, Gopalakrishnan A, Khan A, Grebert Wade D, Strong PA, Manouvrier E, Morgan LT, Span M, Lim JY, Cadiz R, Ung C, Thomas DM, Tucker KM, Warby M, McCowage GB, Dalla-Pozza L, Byrne JA, Saletta F, Fellowes A, Fox SB, Norris MD, Tyrrell V, Trahair TN, Lock RB, Cowley MJ, Ekert PG, Haber M, Ziegler DS, Marshall GM. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. EMBO Mol Med 2022;14:e14608.

64. Lau LMS, Mayoh C, Xie J, Barahona P, MacKenzie KL, Wong M, Kamili A, Tsoli M, Failes TW, Kumar A, Mould EVA, Gifford A, Chow SO, Pinese M, Fletcher JI, Arndt GM, Khuong-Quang DA, Wadham C, Eden G, Trebilcock P, Joshi S, Alfred S, Gopalakrishnan A, Khan A, Grebert Wade D, Strong PA, Manouvrier E, Morgan LT, Cadiz R, Ung C, Thomas DM, Tucker KM, Warby M, McCowage GB, Dalla-Pozza L, Byrne JA, Saletta F, Fellowes A, Fox SB, Norris MD, Tyrrell V, Trahair TN, Lock RB, Cowley MJ, Ekert PG, Haber M, Ziegler DS, Marshall GM. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. EMBO Mol Med 2021;14:e14608.

65. Lawther AJ, Phillips AJK, Chung NC, Chang A, Ziegler AI, Debs S, Sloan EK, Walker AK. Disrupting circadian rhythms promotes cancer-induced inflammation in mice. Brain Behav Immun Health 2022;21:100428.

66. Lo AC, James LP, Prica A, Raymakers A, Peacock S, Qu M, Louie AV, Savage KJ, Sehn LH, Hodgson D, Yang JC, Eich HTT, Wirth A, Hunink MGM. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma. J Nucl Med 2022;63:543-8.

67. Lokuhetty N, Mohan HM, Kong JC, Heriot AG, Warrier SK. Lateral pelvic sidewall dissection in rectal cancer: case selection and training to optimize outcomes. Br J Surg 2022;109:306-7.

68. Mak B, Lin HM, Kwan EM, Fettke H, Tran B, Davis ID, Mahon K, Stockler MR, Briscoe K, Marx G, Zhang A, Crumbaker M, Tan W, Huynh K, Meikle TG, Mellett NA, Hoy AJ, Du P, Yu J, Jia S, Joshua AM, Waugh DJ, Butler LM, Kohli M, Meikle PJ, Azad AA, Horvath LG. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Med 2022;20:112.

69. Maleki S, Glewis S, Fua T, Liu C, Rischin D, Alexander M, Na L, Lingaratnam S. A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy. Support Care Cancer 2022;30:4243-53.

70. McDowell L, Bossi P. The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer? Int J Radiat Oncol Biol Phys 2022;112:938-41.

71. McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R, Australasian L, Lymphoma G. Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. Leuk Lymphoma 2021;63:1-8.

72. Meiser B, Woodward P, Gleeson M, Kentwell M, Fan HM, Antill Y, Butow PN, Boyle F, Best M, Taylor N, Bell K, Tucker K. Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients. Fam Cancer 2022;21:157-66.

73. Min ST, Roohullah A, Tognela A, Jalali A, Lee M, Wong R, Shapiro J, Burge M, Yip D, Nott L, Zimet A, Lee B, Dean A, Steel S, Wong HL, Gibbs P, Lim SH. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an australian population. Asia Pac J Clin Oncol 2022;18:e56-e63.

74. Nedumannil R, Leitinger E, Juneja S. Extreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism. Clin Pathol 2022;15:2632010x221083218.

75. Osong B, Masciocchi C, Damiani A, Bermejo I, Meldolesi E, Chiloiro G, Berbee M, Lee SH, Dekker A, Valentini V, Gerard JP, Rödel C, Bujko K, van de Velde C, Folkesson J, Sainato A, Glynne-Jones R, Ngan S, Brændengen M, Sebag-Montefiore D, van Soest J. Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. Phys Imaging Radiat Oncol 2022;22:1-7.

76. Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. J Thorac Oncol 2022;17:568-77.

77. Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, Gedye C, Kwan EM, Hauser C, Azad AA, Eu P, Martin AJ, Joshua AM, Emmett L. (177)Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. J Nucl Med 2022;63:560-6.

78. Pirie K, Doane MA, Riedel B, Myles PS. Analgesia for major laparoscopic abdominal surgery: a randomised feasibility trial using intrathecal morphine. Anaesthesia 2022;77:428-37.

79. Prabahran A, Koldej R, Chee L, Ritchie D. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. Blood Adv 2022;6:1947-59.

80. Prabhakaran S, Yang TWW, Johnson N, Bell S, Chin M, Simpson P, Carne P, Farmer C, Skinner S, Warrier SK, Kong JC. Latest evidence on the management of early-stage and locally advanced rectal cancer: a narrative review. ANZ J Surg 2022;92:365-72.

81. Prall OWJ, Browning J, Nastevski V, Caporarello S, Bates B, Hewitt CA, Arenas A, Lamb G, Howlett K, Arnolda R, Adeloju R, Stuart S, Xu H, Fellowes A, Fox SB. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance. Pathology 2022;54:279-85.

82. Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Jr., Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol 2022;128:105815.

83. Seidel C, Hentrich M, Zschabitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). World J Urol 2022;40:355-61.

84. Siva S, Ali M, Guckenberger M. Pre-emptive or reactive? PROMPT spinal screening in metastatic castration-resistant prostate cancer. Lancet Oncol 2022;23:443-4.

85. Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A AA, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. Eur Urol 2021;81:364-72.

86. Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A AA, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. Eur Urol 2022;81:364-72.

87. Siva S, Louie AV. Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma - buying time or time to change? Nat Rev Urol 2022;19:197-8.

88. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Jr., Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol 2022;23:362-73.

89. Soh KT, Came N, Otteson GE, Jevremovic D, Shi M, Olteanu H, Natoni A, Lagoo A, Theakston E, Oskarsson J, Gorniak M, Grigoriadis G, Arroz M, Fletcher M, Lin P, Ludwig P, Tembhare P, Matuzeviciene R, Radzevicius M, Kay S, Chen W, Cabrita C, Wallace PK. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis. Cytometry B Clin Cytom 2022;102:88-106.

90. Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, Investigators ET, the A, New Zealand U, Prostate Cancer Trials G. Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. J Clin Oncol 2021;40:JCO2100941.

91. Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ. Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. J Clin Oncol 2022;40:837-46.

92. Tabernero J, Andre F, Blay JY, Bustillos A, Fear S, Ganta S, Jaeger D, Maio M, Mileshkin L, Melero I. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. ESMO Open 2022;7:100419.

93. Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, Teh BW. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv 2022;6:2014-34.

94. Thompson JR, Smith AL, Lo SN, Kasparian NA, Saw RP, Dieng M, Seaman L, Martin LK, Guitera P, Milne D, Schmid H, Cust AE, Bartula I. Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma. BMJ Open 2022;12:e054337.

95. Tjokrowidjaja A, Lord SJ, John T, Lewis CR, Kok PS, Marschner IC, Lee CK. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. Cancer 2022;128:1574-83.

96. Tjong MC, Louie AV, Singh AK, Videtic G, Stephans K, Plumridge N, Harden S, Slotman BJ, Alongi F, Guckenberger M, Siva S. Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung - The Knockout Punch. Clin Oncol (R Coll Radiol) 2022;34:e183-e94.

97. Tobar LE, Farnsworth RH, Stacker SA. Brain Vascular Microenvironments in Cancer Metastasis. Biomolecules 2022;12.

98. Udovicich C, Ng SP, Tange D, Bailey N, Haghighi N. From Postoperative to Preoperative: A Case Series of Hypofractionated and Single-Fraction Neoadjuvant Stereotactic Radiosurgery for Brain Metastases. Oper Neurosurg (Hagerstown) 2022;22:208-14.

99. Vaidyanathan S, Salmi TM, Sathiqu RM, McConville MJ, Cox AG, Brown KK. YAP regulates an SGK1/mTORC1/SREBP-dependent lipogenic program to support proliferation and tissue growth. Dev Cell 2022;57:719-31.e8.

100. van de Ven M, M IJ, Retèl V, van Harten W, Koffijberg H. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer. BMC Med Res Methodol 2022;22:83.

101. Wang M, Zadeh S, Pizzolla A, Thia K, Gyorki DE, McArthur GA, Scolyer RA, Long G, Wilmott JS, Andrews MC, Au-Yeung G, Weppler A, Sandhu S, Trapani JA, Davis MJ, Neeson PJ. Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. J Immunother Cancer 2022;10.

102. Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res 2022;24:17.

103. Weld-Blundell IV, Grech L, Learmonth YC, Marck CH. Lifestyle and complementary therapies in multiple sclerosis guidelines: Systematic review. Acta Neurol Scand 2022;145:379-92.

104. Xu JJ, Chalk AM, Nikolic I, Simpson KJ, Smeets MF, Walkley CR. Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation. Blood Adv 2022;6:2092-106.

105. Ye Z, Li S, Dite GS, Nguyen TL, MacInnis RJ, Andrulis IL, Buys SS, Daly MB, John EM, Kurian AW, Genkinger JM, Chung WK, Phillips KA, Thorne H, Winship IM, Milne RL, Dugue PA, Southey MC, Giles GG, Terry MB, Hopper JL, for k. Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). Cancer Prev Res (Phila) 2021;15:185-91.

106. Yeoh ZH, Roberts AW. Acute leukaemia in Australia: outcomes have improved, but there is still much to do. Med J Aust 2022;216:289-90.